イチキ　ヨシノブ   ICHIKI Yoshinobu   市来　嘉伸    所属   埼玉医科大学  医学部 国際医療センター　呼吸器外科    職種   専任講師
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読なし
表題	Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
掲載誌名	正式名：Journal of UOEH
巻・号・頁	40(2),173-189頁
著者・共著者	Kazue Yoneda,Naoko Imanishi,Yoshinobu Ichiki,Fumihiro Tanaka
発行年月	2018
概要	Cancer immunotherapy with immune checkpoint inhibitors (ICIs) has become a"game changer"in the treatment of advanced non-small cell lung cancer (NSCLC). Its most clinically important advantage over traditional chemotherapy using cytotoxic agents are its long-term survival benefits, and some advanced NSCLC patients treated with an antibody against programmed cell death 1 (PD-1) have survived for 5 years or longer. Immune checkpoint inhibitors (ICIs) are also potentially useful for earlier-stage NSCLC when used in combination with surgery or radiotherapy. A recent clinical trial has shown that consolidation treatment with an antibody against a ligand of PD-1 (PD-L1) following chemo-radiotherapy significantly improves progression-free survival for patients with locally advanced NSCLC. However, current single-agent treatment with an anti-PD-1/PD-L1 antibody may provide significant survival benefits only in a small subset of patients. PD-L1 expression status on tumor cells is an approved biomarker to predict response to ICIs, but is not enough for optimal patient selection. To improve the therapeutic outcomes, development of novel biomarkers other than PD-L1 expression status is essen
DOI	10.7888/juoeh.40.173
PMID	29925736